Drug reference
tegoprazan
Potassium-competitive acid blocker · Antacid
Potassium-competitive acid blockerAntacid
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
—
none in our sources
PREGNANCY
—
not curated
Mechanism
Potassium-competitive acid blockers are weak bases that bind competitively and reversibly to the potassium binding site of the H+/K+-ATPase following protonation. This prevents access of K+ cations to their binding site, blocking activation of the H+/K+-ATPase.
Indications
Erosive esophagitisNonerosive reflux disease
Dosing
- Adult
- 50 mg daily
Pharmacokinetics
Onset
Early onset of action with immediate full effect from the first dose.
Half-life
2 to 9 h
Contraindications
- Only available in Asia
Side effects
Common
DiarrheaNasopharyngitisDyspepsiaHeadacheAbdominal pain
Related guidelines
Other Potassium-competitive acid blocker drugs
Ask House about tegoprazan
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e·Verified: 2026-05-10 · House clinical team